Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Open access
Zhou, Han-Jie, Aujay, Monette A., Bennett, Mark K., Dajee, Maya, Demo, Susan D., Fang, Ying, Ho, Mark N., Jiang, Jing, Kirk, Christopher J., Laidig, Guy J., Lewis, Evan R., Lu, Yan, Muchamuel, Tony, Parlati, Francesco, Ring, Eileen, Shenk, Kevin D., Shields, Jamie, Shwonek, Peter J., Stanton, Timothy, Sun, Congcong M., Sylvain, Catherine, Woo, Tina M., Yang, Jinfu·2009·Journal of Medicinal Chemistry

Abstract

Proteasome inhibition has been validated as a therapeutic modality in the treatment of multiple myeloma and non-Hodgkin's lymphoma. Carfilzomib, an epoxyketone currently undergoing clinical trials in malignant diseases, is a highly selective inhibitor of the chymotrypsin-like (CT-L) activity of the proteasome. A chemistry effort was initiated to discover orally bioavailable analogues of carfilzomib, which would have potential for improved dosing flexibility and patient convenience over intravenously administered agents. The lead compound, 2-Me-5-thiazole-Ser(OMe)-Ser(OMe)-Phe-ketoepoxide (58) (PR-047), selectively inhibited CT-L activity of both the constitutive proteasome (beta5) and immunoproteasome (LMP7) and demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It was well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equivalent to intravenously administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models. The favorable pharmacologic profile supports its further development for the treatment of malignant diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm801329v

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 272

Metadata

Authors
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., Lewis, E. R., Lu, Y., Muchamuel, T., Parlati, F., Ring, E., Shenk, K. D., Shields, J., Shwonek, P. J., Stanton, T., Sun, C. M., Sylvain, C., Woo, T. M., & Yang, J.
Venue
Journal of Medicinal Chemistry
Published
2009-04-06
Volume
52
Issue
9
Pages
3028-3038
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2033944464
Cited by
272
References
37
FWCI
8.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047). https://app.cochat.ai/papers/10.1021/jm801329v
The paper
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., Lewis, E. R., Lu, Y., Muchamuel, T., Parlati, F., Ring, E., Shenk, K. D., Shields, J., Shwonek, P. J., Stanton, T., . . . Yang, J. (2009). Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047). Journal of Medicinal Chemistry. https://doi.org/10.1021/jm801329v

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.